The phenotypic changes which accompany the malignant transformation of normal cells reflect in all probability an underlying change in the genotype or of its expression. This is akin to the induction/repression of regulated genes (Caplan & Ordahl, 1978) during the differentiation process, the aberrant expression of which may also lead to the cancerous state (Wald et al., 1978) . Comparisons of the transcribed genome using differential hybridisation techniques (St John & Davis, 1979) have been used to identify and isolate several genes that have altered transcriptional levels associated with human leukaemias (Shiosaka & Saunders, 1982) and with gastric neoplasms (Shiosaka et al., 1987) . Such studies could also provide clinically useful diagnostic and prognostic markers which would be of particular value in very heterogeneous cancers such as those of the breast. Two-thirds of human mammary carcinomas are oestrogen receptor (ER) rich and thus ER status has become a valuable predictor for response to endocrine therapy (Jensen & DeSombre, 1977) , and may have some prognostic value (Coombes, 1987) . However, about half of patients whose tumours express ER still fail to respond (Osborne et al., 1980) to anti-oestrogens, and this has prompted a search for oestrogen responsive elements which could serve as better indicators. A number of oestrogen-stimulated proteins have been described, principally using the MCF-7 cell line (Horwitz & McGuire, 1978; Butler et al., 1979; Edwards et al., 1980; Westley & Rochefort, 1980) , but none of these have proved to be as useful as ER status.
More recently, differential hybridisation of MCF-7 cDNA libraries with reverse transcribed mRNA isolated from hormone treated and untreated cells has resulted in the cloning of several oestrogen responsive genes (Masiakowski et al., 1982; Prud'homme et al., 1985; . At least one of these, the pS2 gene, has been the subject of intensive study by the same group (Jeltsch et al., 1987; Nunez et al., 1987; Rio et al., 1987) .
Our approach has been to study differential gene expression in a human cancer, compared (Engel & Young, 1978) and human squamous carcinoma cell lines (Easty et al., 1981) were used in this study. Breast cell lines were MCF-7 (two sources of this line were used: Dr M. Lippman, NCI, Bethesda, MD, USA, and the laboratory of origin, the Michigan Cancer Foundation), T47D (Dr H. Freake, (Dr M. Lippman). Squamous cell lines were LICR-LON- Gusterson, Institute of Cancer Research, Sutton, Surrey, UK). All cell lines were maintained in DMEM with 10% FCS and penicillin/streptomycin except for MCF-7 from Dr M. Lippman, which were maintained in similar medium supplemented with 10pgml-1 insulin, 10-8M oestradiol and non-essential amino acids.
Preparation of human breast organoids Organoids (Stampfer et al., 1980) MgCl2, 0.2M Tris/HCl, pH7.5), and incubation at'45°C for 2h. During the incubation the lysates were passed several times through a 0.6mm diameter syringe needle to shear the DNA.
Lysates were cleared by centrifugation at 10,000g for 10min and poly(A)+RNA was extracted by affinity chromatography on oligo (dT)-cellulose (Maniatis et al., 1982) . Its quality was checked by ability to produce translation products in vitro using the rabbit reticulocyte lysate system (Amersham Int. plc) in the presence of 14C-methionine (Amersham Int. plc) according to published methods (Davis et al., 1986) , and labelled products were analysed by polyacrylamide gel electrophoresis (10% PAGE/ SDS gels) (Laemmli, 1970) .
All other RNA used in this study was extracted from cells and biopsy material by the guanidine isothiocyanate method (Chirgwin et al., 1979 (Huynh et al., 1985) . Following hybridisation, filters were washed with five changes of 2 x SSC, 0.1% SDS at 25°C, and two changes of 0.2 x SSC, 0.1% SDS at 55-60°C.
Subeloning into pBr322 cDNA inserts from Agtl 1 phage DNA were excised with EcoRl, ligated into pBR322 plasmid (Biolabs) in the EcoRl site, and transformed in E. coli JM109. Plasmid DNA was isolated by the alkaline lysis method (Birnboim & Doly, 1979) , and insert was removed by EcoRl digestion, purified by preparative agarose gel electrophoresis, and labelled with 32p or 35S-dCTP (Amersham) by the random primer method (Feinberg & Vogelstein, 1983) to specific activities of 109 c.p.m. pg-and 1.5 x 108 c.p.m. pg-DNA respectively.
DNA sequencing
The Md2 cDNA was excised from Agtl 1 phage DNA with EcoRl and inserted into the M13 vectors mp8 and mp9. Single stranded templates were prepared from recombinant plaques and subjected to dideoxy chain termination sequencing (Vieira & Messing, 1982) .
Dot blot hybridisation and Northern analysis
As most biopsies were small and the RNA extracted was generally low, hybridisation was normally performed using total rather than poly(A) + RNA. Wherever possible dot blots were done using serial dilutions of formaldehyde or glyoxal denatured RNA ranging from 10-20 pg to 1.25 pg, spotted on to Biodyne A nylon membrane (Pall Filtration, Portsmouth, UK) using a Bio-dot manifold (Bio-Rad, UK).
Northern analysis of total RNA (20 pg per lane) or poly(A)+ RNA (2.5 pg per lane) was carried out following transfer from agarose/formaldehyde gels (Seed, 1982) . Transcripts were sized using denatured RNA and DNA markers. Hybridisation was carried out as described for library screening above, except 32P-labelled Md2 cDNA at 0.5-1.0 x 107 c.p.m. ml-was employed as the probe, and filters were washed to a higher stringency (0.1 x SSC, 0.1% SDS at 60-65°C).
The autoradiograms were quantified by comparison with an Md2 standard and dots were given a value ranging from 0 (undetectable), ±+ (just detectable above background) to + + + +. The highest intensity represents 100 pg of hybridisable message per 20 pg total RNA. DNA preparation and Southern blotting Tumour samples and cells, stored in liquid nitrogen, were thawed to 25°C in 5 volumes of 10mM NaCI, 1 mM EDTA, 10mM Tris pH 8, and disrupted with a polytron. Sarkosyl, 0.1 volumes of 10% (w/v) solution, and proteinase K (to 200upgml-1) were then added and the homogenate incubated, with agitation, at 25°C for 2 h. The solution was extracted twice with an equal volume of phenol (saturated with 1 M Tris pH8) and twice with an equal volume of chloroform-isoamyl alcohol (24:1) and the DNA precipitated with ammonium acetate and isopropanol dissolved in 5-lOml TE (10mM Tris, lmM EDTA, pH7.5) and reprecipitated with ethanol. The DNA was then dissolved in 10mM TE and digested in 10pg aliquots for 24h with 80u EcoR1 or 60u HindIII or BamHI (NBL), ethanol precipitated, electrophoresed in 0.8% agarose gels (Maniatis et al., 1982) and transferred to Biodyne A nylon membranes (Southern, 1975) . Hybridisation of Southern filters were carried out essentially as described above, using 32P-labelled Md2.
In situ hybridisation The procedure was a modification of that described by Barrett-Lee et al. (1987) after Lawrence & Singer (1985 (1986) ; or by an immunocytochemical assay (ERICA) using the H222 monoclonal antibody kit (Abbott Laboratories, Chicago, USA). The staining procedure has been described in detail elsewhere (McClelland et al., 1986) .
Results

Organoids
The viability of organoids estimated by trypan blue exclusion was greater than 80% in all preparations. Frozen sections were taken from some preparations and stained for myoepithelial cells and blood vessels by immunoperoxidase using the monoclonal antibody LICR-LON-59.2. The organoids in these sections showed well preserved morphology with intact layers of myoepithelial and epithelial cells similar to breast in situ (Figure 1) . From the sections examined it was estimated that blood vessels constituted less than 5% of the tissue in the organoid preparations.
Products from the in vitro translation of organoid poly(A) + RNA were analysed by SDS-PAGE alongside those from MCF-7. Both showed numerous polypeptides (many in common) as discrete bands up to about 90 kD and more weakly staining bands at higher molecular sizes (data not shown). Thus the poly(A) + RNA from both MCF-7 and organoids were of comparable quality.
Differential screening A screen involving about 20% of the phage from the Agtl 1 MCF-7 cDNA library yielded six clones which showed differential hybridisation to 32P-cDNA made from poly(A)+RNA of normal breast organoids or MCF-7 cells. One of these, designated Md2, gave a very strong signal with 32P-MCF-7 cDNA but none with 32P-organoid cDNA. The cloned Md2 Agtl 1 phage was subjected to a differential screen with cDNA derivecd from mRNA of MCF-7 and cut at a thickness of 6 pm, air dried for 2 h and fixed in acetone....... for 5em at 4NC. The immunoperoxidase staining procedure followed published procedures (Gusterson et al., 1985) . The myoepithelial cells of ducts and lobular alveoli units were stained with this antibody whereas the epithelial cells lining the lumen were unstained. Most of the cells in organoid preparations as shown here were organised into duct-like structures similar to those of whole tissue sections (original magnification: x 120).
organoids of different sources to those used in the primary screen, with the same result. The Md2 cDNA insert was subcloned into pBR322, and found to hybridise to about 0.067% of the clones in the library, suggesting a highly represented sequence.
Size of Md2 mRNA Northern blot analysis of MCF-7 mRNA indicated hybridisation of the Md2 cDNA corresponding to a major mRNA species of approximately 0.6-0.7kb (Figure 2) . Sometimes a faint band of about 3 kb could be seen with MCF-7 cells with very much longer exposures. We also saw this using pS2 clone. No signal was seen with a primary breast ER negative carcinoma, a fibroadenoma and MDA-MB-23 1 cells.
Southern analysis
Southern blotting analysis with 32P-Md2 cDNA was performed on DNA from cell lines and breast tumours digested with EcoRl (Figure 3 ), BamHl and Hindlll. This yielded discrete bands of 3.1 and 9.0kb for EcoRl, 3.5 and 7.9kb for BamHI and 4.9kb and >21 kb for Hindlll (data not shown). No difference was observed between Md2 mRNA positive and negative tumours. We also found bands of 5.9kb and 2.1 kb for EcoRl digested DNA of MCF7, which could also be seen as very faint bands in the tracks of breast cell lines ZR-75-1, MDA-MB-231 and T47D, and an organoid preparation.
Sequence analysis of Md2 clone The Md2 cDNA was sequence using the dideoxy chain termination technique. Figure 4 shows the nucleotide sequence between the EcoRI linker insertion sites. There is a short open reading frame with a termination codon. Com- parison of this sequence with that of pS2 (Jakowlew et al., 1984) showed complete homology for nucleotides (Figure 4 ) with only two differences (underlined), one of which has also been reported by Prud'homme et al. (1985) . Thus most of the Md2 corresponds to the 31-untranslated region of pS2 mRNA. Nucleotides 1-53 are unrelated to pS2, and we can only surmise that this sequence became attached to the remainder, during the linker ligation to blunt ended cDNA in the construction of the library. (Jakowlew et al., 1984) . In situ hybridisation Specific localisation was observed in breast cancer cell lines MCF-7 and ZR-75-1 (Figure 6a-d Marked heterogeneity of expression is reflected in the varied grain densities shown in the cytoplasm of these cells (original magnification x 870). Hybridisation was carried out using 35S-labelled probes of comparable specific activity at 37°C for 4 h; autoradiography was 3-4 days. Cells were counterstained in Mayer's Haematoxylin to highlight cell nuclei. specific hybridisation with Md2 when compared with controls.
Hybridisation of Md2 was also visualised in a number of cases of ER positive breast carcinoma (Figure 7) . We found good agreement between this method and measurement using filter hybridisation. Specific hybridisation to the tumour cell component of the sections was noted while only background levels were observed in the stromal tissue. Ducts of histologically normal appearance in tumour sections did not show any significant reactivity. Distribution ofpS2 mRNA in breast tumours: comparison with oestrogen receptor We examined pS2 expression (Figure 8 ) in a total of 54 tumours (49 primaries and five secondaries) by dot blot hybridisation, and found varying levels of message (+ to + + + + ) clearly detectable above background signal seen with poly A-RNA in 23 cases (43%). In four other cases very low (±) levels of pS2 were observed. Only 1/5 secondary carcinomas was positive (+) .
The ER status of the tumours was determined by ERICA in all but eight cases (which had previously been assayed by the DCC method) and compared with pS2 expression. The results are shown in Table I ; 38 (70%) were ER +ve and 16 (30%) ER -ve which agrees well with previous data on this distribution. In the ER +ve group 20/38 (53%) were pS2 +ve (+level or more), whereas in the ER -ve cancers 3/16 (19%) were pS2 +ve. All these were primary infiltrating ductal carcinomas. There was no difference in Md2 hybridisation between pre-and post-menopausal patients, with 47% and 54% positivity, respectively. Nodal involvement was also uncorrelated. From one patient we assayed both the primary tumour and a local recurrence obtained after tamoxifen and medroxyprogesterone acetate treatment. While both had ER +ve cells, only the primary expressed pS2 (+level).
In order to determine whether there was any correlation between pS2 expression in the primary tumour compared to ER status and the response of the patient to endocrine therapy, we performed the following analysis for 21 patients: for ER, a cut off point was taken of > 15 fmol mg-1 cytosol protein (DCC method) or >50% of cells stained (using ERICA) for assessment of positivity. For Md2, the cut off point was + or below. Outcome of therapy was assessed using UICC criteria (Hayward et al., 1977 The results shown in Table II demonstrate that pS2 expression could correctly predict outcome of therapy in 76% of the patients (P=0.041; Fisher's exact test (onetailed)), compared with 75% for ER. There did not appear to be any greater benefit in adding both predictors.
Discussion
We adopted the method of differential hybridisation (St John & Davis, 1979) in a search for differences in gene expression between normal and malignant breast, which could result in isolation of clones that may have clinical (Masiakowski et al., 1982; Prud'homme et al., 1985; ) and progestin regulated genes in breast cancer (Chalbos et al., 1986) . One oestrogen regulated sequence first isolated by Masiakowski et al. (1982) , subsequently by Prud'homme et al. (1985) and probably also by is the pS2 gene. Sequence analysis of the Md2 clone showed that it essentially encoded most of the 3'-untranslated region homologous to pS2.
The pS2 gene is reported to be expressed predominantly in ER positive breast cancers (97% of pS2 mRNA positive cancers being ER positive (Rio et al., 1987) ). We found it to be significantly expressed in 3/16 (19%) ER negative tumours. Also pS2 mRNA has been reported as undetectable in benign breast tumours (Rio et al., 1987) whereas we found Md2 hybridisation, albeit at low levels in 4/5 fibroadenomas. These differences are probably due to the higher specific activity (109 c.p.m. g-') of our probes (compared to 108c.p.m. ig-' (Rio et al., 1987) ). Md2 hybridisation was also found in an ovarian carcinoma (data not shown). It is possible that the patient whose primary tumour but not the recurrence expressed Md2 (although ER status had remained unchanged) did so as a result of the tamoxifen therapy. Recently Rio et al. (1988) reported pS2 expression in normal human stomach, which we have also found (Bennett et al., 1989) . They were unable to detect pS2 in any other normal tissue except salivary gland.
Southern blotting analysis of the Md2/pS2 gene using DNA from Md2 mRNA positive and negative breast tumours, digested with EcoR1 (Figure 3 ), BamHl and Hindl 11l gave similar results for Md2 positive and negative tumours. This indicates that the lack of Md2 expression is not due to an absence of the gene; similarly high pS2 expression is not due to gene amplification. The slight differences in the intensities shown in Figure 3 were due to differences in loading as judged by the ethidium bromide staining before transfer.
The banding pattern was very similar to that reported for the pS2 gene (Jeltsch et al., 1987) . Results with BamHl and Hindl 11 digested DNA were similar to those seen using pS2 but the Md2 also revealed additional fragments, namely a 4.9kb Hindl 11 fragment and 7.9kb BamH1 fragment. There were also two extra EcoRI bands in the MCF-7 track (Figure 3 ), which could be seen as very faint bands in the tracks of the other breast cell lines and an organoid preparation but not in any tumour. The significance of these additional bands, which were not reported for pS2, remains to be seen. They could be ascribed to hybridisation by nucleotides 1-53 of Md2. However, this portion does not contribute to the RNA hybridisation as only the pS2 mRNA band was observed.
As reported previously (Barrett-Lee et al., 1987) we found that results obtained using in situ hybridisation correlate well with the filter hybridisation method. We were able to observe good localisation of Md2 to cancer cells. It was not clear whether myoepithelial cells, which can still be seen in intraductal carcinomas, expressed Md2 to the same extent as the epithelial cancer cells, but no significant reaction was seen in the stromal tissue or vascular elements. This technique will prove very useful in our intended studies of Md2 (and other clones) in needle aspirates, in which we hope to measure expression throughout the course of endocrine therapy.
The value of ER status in predicting response to endocrine therapy (Coombes, 1987) has been evident for some time.
Here, we have shown that Md2 may be an equally reliable predictor of response. Like ER, its expression was significantly related to outcome of therapy. It should also be noted that of the three responders who were put into the Md2 'negative' category (refer to Table II) only one had a zero level for Md2. Therefore it may be that a re-assessment of our cut-off point for Md2 will improve its predictive value. In view of its relative abundance (and hence ease of detection) compared to ER this mRNA could prove to be a valuable marker. As with most analyses of this kind it is important to keep sample numbers in perspective. We hope to obtain more clinical data from patients presently undergoing primary endocrine therapy to provide a larger group for statistical analysis, before coming to any firm conclusions on the usefulness of pS2 as a clinical marker.
